Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The association between telomerase reverse transcriptase (TERT) promoter mutations and some clinical behaviors in thyroid cancer remains controversial and requires additional investigation.
|
31655978 |
2020 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Of late, recurrent promoter mutations in the telomerase reverse transcriptase gene have been intimately coupled to subsets of well-differentiated thyroid cancer specimen with aggressive clinical characteristics as well as less differentiated forms of thyroid cancer with exceedingly poor prognosis.
|
31131695 |
2019 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the association between TERT promoter mutations and recurrence in a prospective series of 173 intermediate- to high-risk patients with thyroid cancer.
|
30648628 |
2019 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to search for novel TERT promoter mutations and additional mechanisms of TERT activation in thyroid cancer.
|
31408918 |
2019 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
LncRNA FOXD2-AS1 Functions as a Competing Endogenous RNA to Regulate TERT Expression by Sponging miR-7-5p in Thyroid Cancer.
|
31024447 |
2019 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recently, telomerase reverse transcriptase (<i>TERT</i>) gene promoter (<i>TERTp</i>) mutations (C228T and C250T) were reported at high frequency in TC cell lines and tumor biopsies.
|
31549911 |
2019 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Telomerase reverse transcriptase (TERT) promoter mutations have been described in different pathological types of thyroid cancers (TC).
|
30024548 |
2018 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, TERT could induce thyroid carcinoma cell proliferation mainly through the PTEN/AKT signaling pathway.
|
29901196 |
2018 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Telomerase reverse transcriptase (TERT) promoter mutations have recently been identified as an important prognostic factor in thyroid cancer.
|
30102829 |
2018 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Telomerase reverse transcriptase (<i>TERT</i>) promoter mutations have been linked to adverse clinical parameters in thyroid cancer, but <i>TERT</i>-expressing tumours are not always mutated.
|
29692346 |
2018 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The DNA methylation and rs2736100 polymorphisms in the promoter region of hTERT gene might be in correlation to postoperative recurrence of TC patients.
|
28587656 |
2017 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The study explored the association between rs10069690C/T and rs2736100G/T of human telomerase reverse transcriptase (hTERT) gene, and the prognosis of thyroid cancer.
|
27472887 |
2016 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Co-regulation of TERT suggests a mechanism by which allelic variants in/near FOXE1 are associated with thyroid cancer risk.
|
27852061 |
2016 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recent reports suggest that mutations in the promoter of the gene encoding telomerase reverse transcriptase (TERT) affect thyroid cancer outcomes.
|
26969876 |
2016 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A telomerase reverse transcriptase (TERT) promoter mutation was identified in thyroid cancer.
|
26727717 |
2016 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thus, TERT with promoter mutations represents a prominent new oncogene in thyroid cancer and the mutations are promising new diagnostic and prognostic genetic markers for thyroid cancer, which, in combination with BRAF V600E mutation or other genetic markers (e.g.
|
26733501 |
2016 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Two mutations (C228T and C250T) in the promoter region of the telomerase reverse transcriptase (TERT) have recently been described in different types of cancer including follicular cell-derived thyroid cancer (TC).
|
26902827 |
2016 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This suggests an important role of TERT mutational analysis in the clinical diagnosis and management of thyroid cancer patients.
|
25951319 |
2016 |
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TERT protein was found to be more expressed in neoplastic than in normal tissues, and to display a different cellular localization, suggesting that it could contribute to thyroid cancer progression by mechanisms taking place in the cytoplasm.
|
25448848 |
2015 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thus, this study on a large cohort of TC patients from Middle East demonstrates that TERT promoter mutations are relatively common, especially in the non-CPTC, and are associated with more aggressive histopathological features, BRAF(V600E) mutation, and disease persistence/recurrence than the WT TERT.
|
26354077 |
2015 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Detailed analysis of TERT across cancers shows that the strength of this association is highly variable and is strongest in copy number-stable cancers such as thyroid carcinoma.
|
25383969 |
2014 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Two promoter mutations, chr5:1 295 228C>T and chr5:1 295 250C>T, in the gene for telomerase reverse transcriptase (TERT) have been recently identified in thyroid cancers and shown to be important in thyroid tumor pathogenesis.
|
25121551 |
2014 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Detailed analysis of TERT across cancers shows that the strength of this association is highly variable and is strongest in copy number-stable cancers such as thyroid carcinoma.
|
25383969 |
2014 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations 1 295 228 C>T and 1 295 250 C>T (termed C228T and C250T respectively), corresponding to -124 C>T and -146 C>T from the translation start site in the promoter of the telomerase reverse transcriptase (TERT) gene, have recently been reported in human cancers, but not in thyroid cancers yet.
|
23766237 |
2013 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In thyroid cancers, the presence of TERT promoter mutations (when occurring together with BRAF mutations) is significantly associated with higher TERT mRNA expression, and in glioblastoma we find a trend for increased telomerase expression in cases harbouring TERT promoter mutations.
|
23887589 |
2013 |